Targets › GPX2
1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 2; Other; next expected readout Dec 2026.
Catalyzes the reduction of hydroperoxides in a glutathione-dependent manner thus regulating cellular redox homeostasis. Can reduce small soluble hydroperoxides such as H2O2, cumene hydroperoxide and tert-butyl hydroperoxide, as well as several fatty acid-derived hydroperoxides. (UniProt, P18283)
Open in Phaseline: the race on GPX2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Sound Pharmaceuticals | Ebselen (SPI-1005) Glutathione peroxidase mimetic | GPX1, GPX2, GPX3, GPX4 | Phase 3 | Meniere's Disease; Hearing Loss | Dec 2026 |
Meniere's Disease (1) Hearing Loss (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.